Toggle navigation
Home
Search
Services
Blog
Contact
About
Therapy for Chemotherapy Alopecia with Pthrp Analogs
Holick, Michael F.
Cutanogen, Inc., Sudbury, MA, United States
Search 146 grants from Michael Holick
Search grants from Cutanogen, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
In situ Imaging of CAR T-cells
RhoB in cancer pathogenesis and as a target in combinatorial therapy
Apoptosis In Neurodegenerative Disorders
Morphological and Functional Aspects of Peptides in Mammalian Brain
Caterpillars and Parasitoids in the Eastern Andes of Ecuador.
Recently added grants:
Nanotherapeutic treatment of the invasive glioblastoma microenvironment
Evaluation of pre-exposure prophylaxis cascade in pregnant and breastfeeding women in Cape Town, South Africa
Precision Medicine Approach: Using genomic information to guide TBI treatment
Testing the Effectiveness of the Customized Career Development Platform (CCDP): A Cluster Randomized Trial
The Discovery of Novel Metabolic Pathways for the Biosynthesis and Degradation of Complex Carbohydrates within the Human Gut Microbiome
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41CA071119-01
Application #
2114842
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (15))
Project Start
1996-08-01
Project End
1997-11-30
Budget Start
1996-08-01
Budget End
1997-11-30
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Cutanogen, Inc.
Department
Type
DUNS #
City
Sudbury
State
MA
Country
United States
Zip Code
01776
Publications
Peters, E M; Foitzik, K; Paus, R et al.
(2001)
A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist.
J Invest Dermatol 117:173-8
Comments
Be the first to comment on Michael Holick's grant